For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Oxigene, Inc.

USPTO Granted Patents = 25

CIPO Patents = 1

EPO Patents = 2

Forward Citations = 99

Loading Chart...

Loading Chart...

35 inventors (with patents filed for the assignee):

David J Chaplin (13 out of 16 patents)

Ronald W Pero (12 out of 24 patents)

Kevin G Pinney (10 out of 22 patents)

4. Klaus Edvardsen (8 out of 10 patents)

5. Joseph Anthony Prezioso (7 out of 7 patents)

6. Charles Manly Garner, Iii (4 out of 4 patents)

7. Robert Ronald Kane (4 out of 6 patents)

8. Zhi Chen (3 out of 12 patents)

9. Vani P Mocharla (3 out of 6 patents)

10. David I Sherris (2 out of 6 patents)

11. Mallinath Hadimani (2 out of 3 patents)

12. James Michael Dorsey (2 out of 6 patents)

13. Alan N Schwartz (1 out of 33 patents)

14. Francis Lee (1 out of 21 patents)

15. Kishore Kumar Gaddale Devanna (1 out of 3 patents)

25 patents: Sort by Forward Citations

1. RE45907 - Functionalized stilbene derivatives as improved vascular targeting agents (2016-02-29),

2. RE45720 - Functionalized stilbene derivatives as improved vascular targeting agents (2015-10-05),

3. 9040500 - Method for treating hematopoietic neoplasms (2015-05-26),

4. 8877967 - Compositions and methods for inhibition of cathepsins (2014-11-04),

5. 8198302 - Compositions and methods with enhanced therapeutic activity (2012-06-12),

6. 7456214 - Chromene-containing compounds with anti-tubulin and vascular targeting activity (2008-11-25),

7. 7384925 - Functionalized stilbene derivatives as improved vascular targeting agents (2008-06-10),

8. 7358236 - Control of acute hypertension and cardiotoxicity in patients treated with vascular targeting agents (2008-04-15),

9. 7091240 - Tubulin binding ligands and corresponding prodrug constructs (2006-08-15),

10. 7037906 - Methods for modulating tumor growth and metastasis (2006-05-02),

11. 7001926 - Tubulin binding agents and corresponding prodrug constructs (2006-02-21),

12. 6956054 - Compositions and methods for use in targeting vascular destruction (2005-10-18),

13. 6919324 - Functionalized stilbene derivatives as improved vascular targeting agents (2005-07-19),

14. 6743937 - Efficient method of synthesizing combretastatin A-4 prodrugs (2004-06-01),

15. 6713517 - Use of aryl N-substituted carboxamides directly and as radio-and chemosensitizers for killing tumor and cancer cells and novel compounds for such use (2004-03-30),

OXiGENE is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat cancer. With a proprietary and versatile drug discovery platform, OXiGENE is dedicated to targeting and inhibiting angiogenesis, the process by which new blood vessels form and grow. By disrupting this process, OXiGENE's therapies have the potential to halt the growth of tumors and improve patient outcomes. For more information about OXiGENE, please visit their website.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

25 Patents

#52 in South San Francisco, CA

#3,062 in California

#12,936 in US

#24,954 in the World

South San Francisco, CA, United States of America

Oxigene, Inc.

Forward Citations = 99

35 inventors:

David J Chaplin (13 out of 16 patents)

Ronald W Pero (12 out of 24 patents)

Kevin G Pinney (10 out of 22 patents)

4. Klaus Edvardsen (8 out of 10 patents)

5. Joseph Anthony Prezioso (7 out of 7 patents)

Please report any incorrect information to support@idiyas.com

Loading…